

For Immediate Release
For Further Information Contact:
Andrew Fisher at (202) 483-7000
Email: Afisher@unither.com

**UNITED THERAPEUTICS REPORTS
THIRD QUARTER 2002 FINANCIAL RESULTS**

Conference Call Scheduled for Friday, November 8, 2002 at 9:00 a.m. E.T.

Silver Spring, MD, November 8, 2002: United Therapeutics Corporation (NASDAQ: UTHR) today announced financial results for the quarter ended September 30, 2002.

"Today, we report that United Therapeutics' total revenues for the quarter ended September 30, 2002 totaled \$5.1 million," said Fred Hadeed, United Therapeutics' Chief Financial Officer. "As of October 31, 2002, there were approximately 500 patients receiving Remodulin® therapy worldwide. Approximately 350 of these are reimbursable patients. Based on the number of reimbursable patients on therapy, the current revenue run rate is estimated at approximately \$30 million per year, up from the previous estimate of \$25 million."

"We are pleased with the results to date," said Martine Rothblatt, Ph.D., United Therapeutics' Chairman and Chief Executive Officer. "While we anticipated lower sales of Remodulin in the third quarter of 2002 as compared to the second quarter of 2002, sales of Remodulin in the fourth quarter to date are at approximately \$8.5 million, which is adequate to cover fourth quarter demand."

Revenues in the third quarter of 2002 were \$5.1 million, as compared to revenues of \$1.3 million in the third quarter of 2001. Cost of sales in the third quarter of 2002 were \$1.3 million, as compared to \$859,000 in the third quarter of 2001. Gross margin from sales was \$3.9 million in the third quarter of 2002, as compared to gross margin of \$457,000 in the third quarter of 2001. These increases were due primarily to sales of Remodulin, which was approved in May 2002, and related pumps and supplies.

United Therapeutics incurred a net loss of \$12.2 million in the third quarter of 2002, compared to a net loss of \$9.8 million in the third quarter of 2001. This represents a loss of \$.58 per share in the third quarter of 2002, as compared with a loss of \$.48 per share in the third quarter of 2001. A large component of the net loss in the third quarter of 2002 was due to a loss on the sales of marketable debt investments totaling \$3.3 million and a write-down of an investment in affiliate totaling \$2.9 million, as discussed below. United Therapeutics incurred a loss from operations of approximately \$6.5 million in the third quarter of 2002, compared to a loss from operations of \$11.9 million in the third quarter of 2001. Had the loss and write-down not been necessary, United Therapeutics would have incurred a net loss of approximately \$6.0 million or \$.29 per share in the third quarter of 2002.

Research and development expenses in the third quarter of 2002 were \$6.6 million as compared to \$8.0 million in the third quarter of 2001. The decrease was due primarily to a reduction in expenses related to patient enrollment in United Therapeutics' clinical trials, offset by an increase in expenses for United Therapeutics' OvaRex® ovarian cancer program. General and administrative expenses in the third quarter of 2002 were \$2.6 million as compared \$3.4 million in the third quarter of 2001. The decrease was due in part to a reduction in expenses related to travel and amortization of goodwill due to the adoption of SFAS No. 142 on January 1, 2002.

Sales and marketing expenses totaled \$1.2 million in the third quarter of 2002, compared to sales and marketing expenses of \$1.0 million in the third quarter of 2001.

Interest income was \$537,000 in the third quarter of 2002 as compared to \$2.2 million in the third quarter of 2001. This decrease was attributable primarily to reductions in market interest rates.

United Therapeutics recorded a loss on sales marketable investments totaling \$3.3 million in the third quarter of 2002. This loss was due to the sale of all marketable debt investments in July 2002 and their reinvestment in money market funds and commercial paper. These sales and reinvestments were made due to the increased volatility in the bond market. United Therapeutics also recorded a write-down of investment in an affiliate totaling \$2.9 million in the third quarter of 2002. This write-down was necessary to adjust the carrying value of United Therapeutics' investment in AltaRex Corp., from which United Therapeutics in-licensed the OvaRex ovarian cancer program, to its fair market value at September 30, 2002.

United Therapeutics will host a teleconference on Friday, November 8, 2002 at 9:00 a.m. Eastern Time to discuss third quarter financial results. The teleconference is accessible by dialing 1-800-915-4836, with international callers dialing 1-973-317-5319. A rebroadcast of the teleconference will be available for one week by dialing 1-800-428-6051, with international callers dialing 1-973-709-2089, and using access code 267343.

United Therapeutics is a biotechnology company focused on combating chronic and life-threatening cardiovascular, infectious and oncological diseases with unique therapeutic products.

Statements made in this press release about drug commercialization, estimated Remodulin revenue run rate, fourth quarter 2002 total revenues, and investment activities are forward-looking statements, which represent United Therapeutics' expectations concerning future events. These expectations are subject to risks and uncertainties such as those described in United Therapeutics' reports on Form 10-K and Form 10-Q as filed with the Securities and Exchange Commission, which may cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in United Therapeutics' reports and documents filed with the Securities and Exchange Commission. United Therapeutics undertakes no obligation to publicly update or revise any forward-looking statements whether as a result of new information, future events or any other reason.

UNITED THERAPEUTICS CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS DATA
(In thousands, except share and per share data)

	Three months ended September 30,		Nine months ended September 30,	
	2002	2001	2002	2001
Revenues:				
Product sales	\$ 4,358	\$ 505	\$ 15,599	\$ 1,729
Service sales	770	572	2,499	1,746
Service sales to affiliates	-	186	-	541
Grant revenue		53		96
Total revenue	<u>5,128</u>	<u>1,316</u>	<u>18,098</u>	<u>4,112</u>
Operating expenses:				
Research and development	6,640	8,014	18,423	26,080
General and administrative	2,580	3,378	8,108	10,374
Sales and marketing	1,170	963	2,499	2,696
Cost of product sales	833	535	2,724	1,094
Cost of service sales	442	324	1,234	1,295
Total operating expenses	<u>11,665</u>	<u>13,214</u>	<u>32,988</u>	<u>41,539</u>
Loss from operations	(6,537)	(11,898)	(14,890)	(37,427)
Other income (expense)				
Interest income	537	2,186	4,396	7,924
Interest expense	(25)	(31)	(90)	(125)
Equity loss in affiliate	(7)	(107)	(151)	(261)
Other, net	65	39	10	28
Write-down of investment in affiliate	(2,893)	-	(2,893)	-
Loss on marketable investments	(3,328)	-	(7,428)	-
Total other income (expense)	<u>(5,651)</u>	<u>2,087</u>	<u>(6,156)</u>	<u>7,566</u>
Net loss before income tax	(12,188)	(9,811)	(21,046)	(29,861)
Income tax	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>
Net loss	<u>\$ (12,188)</u>	<u>\$ (9,811)</u>	<u>\$ (21,046)</u>	<u>\$ (29,861)</u>
Net loss per common share – basic and diluted	<u>\$ (0.58)</u>	<u>\$ (0.48)</u>	<u>\$ (1.02)</u>	<u>\$ (1.47)</u>
Weighted average number of common shares outstanding – basic and diluted	<u>20,899,094</u>	<u>20,250,167</u>	<u>20,550,978</u>	<u>20,306,124</u>

CONSOLIDATED BALANCE SHEET DATA
(In thousands)

	<u>September 30, 2002</u>
Cash and cash equivalents	\$133,807
Total stockholders' equity	\$174,109
Total assets	\$187,473